HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 21 August 2017

NICE ‘yes’ to wider use of bisphosphonates…

…based on the ScHARR-TAG report by Sarah Davis, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi, Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson and Mark Strong.

From the NICE website:

“NICE has published new guidance on the use of drugs called bisphosphonates for preventing bone fractures in people at increased risk.

The new guidance links a person’s risk of having a bone fracture with the point at which treatment should be started, based on cost effectiveness.  It recommends treatment with oral bisphosphonate drugs alendronic acid, ibandronic acid and risedronate sodium as options for people who have at least a 1% risk of a bone fracture within the next 10 years.  The new guidance also recommends the injected bisphosphonates ibandronic acid and zoledronic acid for people who have at least a 10% risk of a bone fracture within the next 10 years.

The guidance says that the 10-year probability of having a bone fracture should be estimated using the FRAX or QFracture risk tools, in line with NICE’s existing guideline on osteoporosis.  For some people with a 1% risk of a bone fracture oral bisphosphonates may be contraindicated or not tolerated, or taking them might be difficult or impossible. For these people injectable bisphosphonates are recommended.”

Image: yes by Asja Boros